PDMR DEALING
5 February 2021
NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the following option award in connection with the appointment of Dr Thomas Adams, Ph.D. as an executive director.
The Board, on the recommendation of the Remuneration Committee, have granted Dr Adams 3,500,000 options under the Company's share option plan. 3,000,000 of the options vest over a 4 year period in equal tranches and have an exercise price of 149 pence per share. The balance of 500,000 options vest on the attainment of clinical milestones relating to the Company's oncology programs with the same exercise price.
The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
|
1.
|
Details of PDMR / person closely associated
|
|
a)
|
Name
|
Dr Thomas Adams
|
|
2.
|
Reason for the notification
|
|
a)
|
Position / status
|
Director, Head of Drug Development
|
|
b)
|
Initial notification /amendment
|
Initial notification
|
|
3.
|
Details of the issuer
|
|
a)
|
Name
|
Tiziana Life Sciences plc
|
|
b)
|
LEI
|
213800CED47HI8PIOB36
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares of 3 pence each
|
|
b)
|
Identification code of the Financial Instrument
|
ISIN for Tiziana Life Sciences plc: GB00BKWNZY55
|
|
c)
|
Nature of the transaction
|
Grant of options
|
|
d)
|
Price(s) and volume(s)
|
|
Price
|
Volume
|
|
149p
|
3,500,000
|
|
|
f)
|
Date of the transaction
|
2 February 2021
|
|
|
|
|
|
g)
|
Place of the transaction
|
XLON
|
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
|
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
|
+44 (0)20 7495 2379
|
U.S. Investor Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
